ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies
Perelman School of Medicine at the University of PennsylvaniaA new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.